Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.
Saved in:
| Title: | Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001. |
|---|---|
| Authors: | Chiorean, Elena Gabriela1,2 (AUTHOR) gchiorea@uw.edu, Damle, Sheela R.1,2 (AUTHOR), Zhen, David B.1,2,3 (AUTHOR), Whittle, Martin2,4 (AUTHOR), George, Ben3,4,5 (AUTHOR), Hochster, Howard5,6 (AUTHOR), Coveler, Andrew L.1,2,7 (AUTHOR), Hendifar, Andrew6,8 (AUTHOR), Dragovich, Tomislav7,9 (AUTHOR), Safyan, Rachael A.1,2 (AUTHOR), King, Gentry T.1,2 (AUTHOR), Harris, William P.1,2,3 (AUTHOR), Dion, Barbara3,4 (AUTHOR), Stoll D'Astice, Amy5,8 (AUTHOR), Lee, Arthur6,8 (AUTHOR), Thorsen, Shelley2,7 (AUTHOR), Kugel, Sita2,8 (AUTHOR), Rosenthal, Adam8,9 (AUTHOR), Hingorani, Sunil2,9 (AUTHOR) |
| Source: | Cancers. Feb2026, Vol. 18 Issue 3, p507. 17p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
